Audrey's Life Science Meeting Picks for May 7, 2017 – June 2017
Complimentary Service of AudreysNetwork.com
May 7, 2017

****

Bio2Device Group, Tuesday Evening, May 9, 2017

Topic: "Liquid Biopsies: A Fundamental Advance in Cancer Care"
Mark Jacobstein, Chief User Engagement Officer, Guardant Health
Date and Time: Tuesday, May 9, 2017
Location: Wilson Sonsini Goodrich & Rosati - 650 Page Mill Road, Palo Alto
Cost:
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins
Register at www.bio2DeviceGroup.org

Topic Description
Liquid Biopsies use circulating biomarker signals (e.g. circulating tumor DNA) found in blood to characterize, and potentially even detect, cancer tumors. Their growth in clinical use for advanced cancer therapy selection is just the start; potential uses include residual disease and early disease detection, and their insights into tumor-genesis and tumor-evolution may be a key for cancer research. Mark Jacobstein, the Chief User Engagement Officer at Guardant Health, the world's leaders in liquid biopsies, will give an overview of this new technology and its current and potential future utility.

Speaker Bio
Mark is the Chief User Engagement Officer for Guardant Health, the world's leaders in liquid biopsies. Mark was the CEO of iSkoot before selling the company to Qualcomm, where he led Qualcomm iSkoot Technologies. Prior Mark was an EVP at loopt, and the founding President of Digital Chocolate. Mark was the CEO and founder of Small World Sports, the world's first online fantasy sports business, which he sold to Paul Allen's The Sporting News. In 1994 Mark co-founded Small World Software, an Internet technology consultancy, which he sold to iXL in 1998
****

QB3, Late Thursday Afternoon, May 11, 2017

Topic: "Leadership in Biopharma: a Conversation with John Milligan, CEO of Gilead Sciences"
Speakers: John Milligan, CEO, Gilead Sciences; Harold E. "Barry" Selick, Ph.D. CEO, Threshold; Brook Byers, Founding Partner of Kleiner Perkins Caufield & Byers
Date and Time: Thursday Afternoon, May 11, 2017, 4:00 – 6:30 pm
Agenda
4:00 pm Introduction: Brook Byers, Partner, Kleiner Perkins Caufield & Byers
4:00-5:00 pm Remarks from John Milligan, Gilead Sciences, followed by audience Q&A and a conversation moderated by Barry Selick, Threshold Pharmaceuticals
5:00-6:30 pm Reception

Location: Byers Auditorium, Genentech Hall, Byers Auditorium, Genentech Hall, UCSF Mission Bay, 600 16th Street. San Francisco, CA 94158

4:00 to 5:00 pm, Thursday, May 11. Reception to follow
Registration is free. Register at https://www.eventbrite.com/e/leadership-in-biopharma-a-conversation-with-john-milligan-ceo-gilead-sciences-tickets-32902967662?mc_eid=cb4c38a44a&mc_cid=c37eecb250#tickets

Background
Gilead Sciences is a Bay Area titan, a life science leader known for its pipeline of antivirals and Hepatitis C therapeutics. Its CEO is John F. Milligan, PhD, a former UCSF postdoc, who joined the company in 1990 as its 32nd employee. Join us on May 11 when Barry Selick, CEO of Threshold Pharmaceuticals and himself a former UCSF postdoc, will engage Milligan in a conversation touching on topics such as Milligan's career path from postdoc to CEO of a major biotech, his experience leading it, and how Gilead feeds its pipeline of innovation and develops new products.
Brook Byers, a Founding Partner of Kleiner Perkins Caufield & Byers and a member of the UCSF Board of Overseers, will provide introductory remarks.

Speaker Bio
Dr. John F. Milligan joined Gilead Sciences in 1990 and was appointed Chief Executive Officer in March 2016. He began his career at Gilead as a research scientist, and subsequently held leadership positions in project management and corporate development before being named Chief Financial Officer in 2002. He was appointed Chief Operating Officer in 2007 and President in 2008.
During his tenure at Gilead, Dr. Milligan has led teams that have developed, manufactured and commercialized more than 20 new therapies for significant unmet needs. He has managed multiple transformative acquisitions, licensing agreements and financings, helping the company grow into a worldwide organization reaching more than 10 million patients. He is a member of the board of Pacific Biosciences of California, Inc. and a Trustee of Ohio Wesleyan University.

Harold E. "Barry" Selick, Ph.D. joined Threshold as Chief Executive Officer in June 2002. Between June 2002 and July 2007, Dr. Selick was also a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company that was acquired by ArQule. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL's first product, Zenapax, which was developed and commercialized by Roche for the prevention of kidney transplant rejection. Dr. Selick received his B.S. and Ph.D. from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.

Brook Byers is a Founding Partner of Kleiner Perkins Caufield & Byers. A venture capital investor since 1972, Brook has been closely involved with more than 60 new technology-based ventures, many of which have become public companies. He formed the first life sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare and biotechnology sectors. KPCB has invested in and helped build more than 170 life sciences companies that have developed hundreds of products to treat underserved medical needs for many millions of patients. Brook was the founding president and

then chairman of four biotechnology companies that were incubated in KPCB's offices and went on to become public companies with an aggregate market value of more than US$8 billion. He serves on the board of directors of Cell Design Labs, Enjoy, Newsela and Zephyr Health. Brook is also a Lifetime Director on the UCSF Board of Overseers.

Bio2Device Group, Tuesday Morning, May 16, 2017

Topic: "Why Can't We Just Produce New Brain Neurons and Reverse Neurodegenerative Disease?"
Speaker: Judith Kelleher-Andersson, Founder, President and CEO, Neuronascent, Inc.
Location: Sunnyvale City Council Chambers- 456 West Olive Ave., Sunnyvale
There is no registration or fees for morning meetings.
Topic Description
There is only marginal, symptomatic relief for the approximately 5.3 million Americans thought to already suffer from Alzheimer's disease (AD). With a decade of failures for neuroprotective agents alone, Neuronascent discovered and developed a therapy that would not just stop further neuron loss and dysfunction, but that would promote new neurons that survive to maturation, replacing those lost. This first-in-class, neuron regenerative agent should then halt or even reverse the memory impairment in Alzheimer's patients. The unique mechanism of action was only determined after the identification of a lead candidate through a phenotypic screening platform and optimization program. Neuronascent aims to submit an IND to the FDA for NNI-362 for Alzheimer's disease in 2017. The NIA supported a pre-IND meeting with the FDA and supported all of the FDA-required GLP safety studies showing the agent to be safe. On obtaining FDA approval to initiate the first-in-human testing of NNI-362 for Alzheimer's disease, Neuronascent aims to determine the safety, tolerability and PK in a healthy volunteers aged 50-72. Male and female volunteers will be administered a single dose of NNI-362 orally at one of three ascending doses (SAD) , with and without food. This will be followed by a 14-day daily ascending dose (MAD) test. Plasma levels of NNI-362 will be assessed to determine pharmacokinetics and whether a pharmacodynamic dose has potentially been reached. If NNI-362 is deemed safe and well-tolerated, the agent could then be tested for ability to promote new neurons and halt or reverse cognitive deficits and reverse impaired function in Alzheimer's patients in POC trials.

Speaker Bio
Dr. Kelleher-Andersson has over twenty years of experience discovering and developing small molecule, central nervous system therapeutics in the biotechnology industry. She has raised equity of over 2 million and obtained a number of state and federal grants related to novel therapeutic development. After founding Neuronascent, Kelleher-Andersson discovered and developed a number of technologies. One lead therapeutic is a first-in-class neuron regenerative agent, that is patented and has competed all GLP safety testing, GMP manufacturing and brings the lead to point of IND application to begin first-in-human testing in healthy aged population.
Prior to founding Neuronascent, Inc, she directed drug development research at Neuralstem, Inc., at Centaur Pharmaceuticals and at Cortex Pharmaceuticals, Inc. She strategically directed research/development and personnel toward finding innovative therapies for neurological indications with large unmet need. She headed the Alzheimer's disease program in collaboration with Astra-Zeneca while at Centaur, and successfully brought a small molecule therapeutic to pre-nomination status (primary inventor). She is primary inventor on a neurogenic depression therapeutic, while at Neuralstem, that is presently in Phase 2b clinical testing. Dr. Kelleher-Andersson has over 70 US, European and World patents. She received her Ph.D. in biochemistry from the University of Missouri-

Columbia and completed post-graduate work at University of California, Los Angeles and at University of California, San Francisco.

****

Engineering in Medicine and Biology Society (EMBS), Wednesday Evening, 7:30 pm

Topic: "Picosecond Pulse Imaging – Promising but Challenging Modality for Wearable Functional and Structural Brain Imaging"
Speaker: Joel Libove, President, Furaxa, Inc.
Date and Time: Wednesday, May 17, 2017, 7:30 PM
Location: Room M-114, Stanford University Medical School (see campus map at link below)
Optional dinner location: Stanford Hospital cafeteria, 6:15 PM (no host, no reservations, self-serve)

The Stanford campus map is at: https://campus-map.stanford.edu/
Parking is usually free after 5 PM at Roth Way Garage, which is at the corner of Roth Way and Campus Drive on the map. The Stanford Hospital Cafeteria is across Campus Drive from Roth Way Garage and near the Emergency entrance. The meeting is in Room M-114 of the Alway Building, which is also across Campus Drive from Roth Way Garage, and Room M114 is accessible from outside the Alway Building.

Topic Description
Ultrawideband (UWB) 10-100 picosecond wide electrical pulses can penetrate through even the deepest brain tissues, and can now be generated and detected using arrays of very low cost, high dynamic range, single chip radars. The ability to make an inexpensive helmet with hundreds of these radars, coupled with their capability for full brain penetration endows Picosecond Pulse Imaging (PPI) with the most promise, at least in theory, for enabling wearable, high resolution portable Brain Machine Interfaces (BMIs) for real time functional imaging. However, structural, vascular and functional images produced by researchers to date have been poor. Approaches will be presented here for significantly improving signal-to-noise ratio (SNR) and mitigating the effects of severe scattering that have prevented this technology from reaching its enormous potential.

Speaker Bio
Joel Libove specializes in high speed electronics, including ultrawideband amplifier circuit design, UWB pulse generation and picosecond electronic sampling. He is president of Furaxa, Inc., where he leads the development of non-invasive microwave-based real-time vascular and functional medical imaging systems. He is also Chairman of Ultraview Corporation where he architected 8 generations of high dynamic range high speed data acquisition boards. Prior to this Dr. Libove developed the first hardware-implemented zero-latency disk controller, the first automatic computer bus violation detector, and the first accurate non-contact AC voltmeter. Joel holds 13 patents (three of which were licensed) and one patent pending. He has a Ph.D. from UC Berkeley, and a BSEE from Cornell University.
****
BioPharma PM Conference, Monday-Wednesday, May 22-24, 2017

Event: Stepping Up and Stepping Out
Dates: Monday, Tuesday and Wednesday, May 22-24, 2017
Program:
May 22
5:00-7:00PM: Registration and Opening Networking Reception
May 23
7:30-9:00AM: Registration and Breakfast Networking
9:00AM-5:00PM: Conference Presentations, Panels, Workshops
5:00-7:00PM: Evening Networking Reception
May 24
7:30-9:00AM: Breakfast Networking
9:00AM-2:30PM: Conference Presentation, Panels, Workshops
2:30PM: Conference Conclusion
Location: San Mateo Marriott San Francisco Airport, 1770 South Amphlett Boulevard, San Mateo, CA 94402
Registration: Early Bird Registration (through March 31): $695 (plus payment processing fees); Regular Conference Registration (after March 17): $895 (plus payment processing fees); All registrants will receive a complimentary one-year BioPharmaPM Network membership (a $50 value).
Register at https://www.eventbrite.com/e/2017-biopharmapm-conference-tickets-31937261208

Event Description
Please join us for the 2017 BioPharmaPM Network Conference! We are planning an exciting program for you. Below are a few of our featured speakers, panelists, and trainers who will speak on diverse topics such as managing your career in alignment with your values, leadership development in project management, and how you can solve problems inhibiting project success easily and effectively.

Speakers: William Schiemann, Founder and CEO of Metrus Group and Author;
Jean Lee, Ph.D., Vice President, Portfolio and Project Management at Pfizer Global Product Development; Michael Young, Chief Learning Officer and SVP of Education at the The Medicines Company;Mark Velligan, Senior Director of Portfolio Management and Operations at Genentech;Trevi Wormley, Managing Director and Chief Solution Engineer at TJ Strategy Group, LLC

We hope you will join us at the San Mateo Marriot in San Francisco May 22-24 and be a part of the only non-profit organization solely committed to project management best practices, development, and networking for biopharma project and program managers.

FAQs
How can I contact the organizer with any questions?
For questions, please contact Kelly Magnuson at kmagnuson@biopharmapm.org
How do I make room reservations?
We are holding a few rooms at a discounted rate with the San Mateo Marriott. If you require a room, please email Kelly Magnuson at kmagnuson@biopharmapm.org for

Golden Gate Polymer Forum , Monday Evening, May 22,2017

Topic: “"Self-Assembly of Polymer-Grafted Nanocrystals via Solvent Annealing"
Speaker: Ricardo Ruiz, Western Digital Corporation

Date and Time: Monday, May 22, 2017
Location: Michaels at Shoreline Restaurant, Mountain View
Location: Michael's at Shoreline, 2960 N Shoreline Blvd., Mountain View
Cost: Employed/postdocs: $30 early registration, $35 regular registration;
Unemployed/retired/students: $15 early registration; $20 regular registration
Free if you attend just the lectures at 8:00 PM (but please let us know for headcount)
After deadline:
Registration not guaranteed, so contact us
Late fee applies if space available -- $40 regular/employed, $25 unemployed/student/retired
Deadlines for registration:
End of discounted advance registration Monday, May 15, 11:59 PM
End of regular (full-price) registration Friday, May 19, 5:00 PM
Please register on the web page, www.GGPF.org<http://www.GGPF.org>

PLEASE NOTE:
We accept cash or checks at the door, but are unable to accept payment by credit card at the event.
You may pay at the door.
Checks may be made to "GGPF"
Discounted advanced registration ends Monday, May 15, 11:59 PM.
Full-price regular registration deadline is Friday, May 19, 5:00 PM.
Register at www.GGPF.org<http://www.GGPF.org> (PayPal is enabled if desired)
Or, if necessary, contact:
Len Radzilowski
lradzilo@te.com<mailto:lradzilo@te.com>
650-361-3264

Topic Description
Nanocrystal superlattices are attractive as building blocks for artificial solids in a wide range of applications including optical, electronic, photovoltaic, thermoelectric and biocompatible devices to name a few. A common challenge to commercialize superlattice-based devices is the difficulty associated in controlling the self-assembly over wafer-scales with monolayer thickness control. Most commonly, nanocrystal superlattices are self-assembled through kinetically-driven methods such as solvent drying mediated assembly, or through complex liquid interfaces that are not compatible with large area, high volume manufacturing. Polymer-grafted nanocrystals (PGNCs) in controlled solvent atmospheres (solvent annealed) are particularly attractive because of their dual colloidal and polymeric properties that facilitate self-assembly towards thermodynamic equilibrium. PGNCs share properties with star polymers, and when the inorganic cores are sufficiently screened by the polymer ligands, their thermodynamic properties can be understood in terms of the Daoud-Cotton model developed for star polymers. In this work we study the assembling properties of Fe3O4 nanocrystals tethered with polystyrene ligands. We confirm swelling and assembly properties according to the Daoud-Cotton model. As predicted for star polymers, we confirm a phase transition as a function of particle density into a hexatic phase. We exploit the polymeric properties of PGNCs to perform directed self-assembly to achieve orientation control over large areas. Overall, the polymeric and colloidal duality of PGNCs open interesting opportunities for the self-assembly of superlattices with an ease of processing typical of polymer films.
.

Speaker Bio
Ricardo Ruiz is a research technologist at Western Digital Corp. His research interests span alternative nanofabrication techniques for storage and memory devices, block copolymer lithography, and colloidal self-assembly. From 2013 to 2016 he managed a Nanopatterning and Self Assembly group at HGST dedicated to block copolymer and colloidal lithography. Prior to that, he was a research staff member at HGST where he helped introducing block copolymer lithography for magnetic bit patterned media technology. Before joining HGST, he was a postdoctoral scientist at IBM T.J. Watson Research Center. He received his PhD in Physics from Vanderbilt University in 2003, has co-authored over 50 publications, and holds 35 US Patents. He is a fellow of the American Physical Society and was the recipient of the 2016 ACS Applied Materials and Interfaces Young Investigator Award. He has also co-taught short courses (on Directed Self Assembly and its Application to Nanoscale Fabrication), along with Prof. Juan de Pablo and Prof. Paul Nealey, at the annual SPIE Advanced Lithography meeting.

****
*

JLABS, Tuesday Morning, May 23, 2017

Topic: "Rough seas or smooth sailing? Navigating Collaboration Agreements"
Speakers:
Angela Rusakova | Lead Client Service and Audit Partner, Deloitte & Touche LLP
Yelda Kaya | Sr. Director Transactions, Johnson & Johnson Innovation
William J. Newell | CEO, Sutro Biopharma
Moderator: Lesley Stolz | Head of JLABS, CA, Johnson & Johnson Innovation, JLABS
Date and Time: Tuesday, May 23, 2017 from 9:00 AM to 11:30 AM (PDT)

Agenda:
9:00 AM | Registration, Breakfast, and Networking
9:30 AM | Components of a collaboration agreement
10:00 AM | Panel Discussion: Implications of Components
11:00 AM | Q&A
11:30 AM | Program Close
Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California
Fees:
$25 | General Public
$15 | Student
Order at https://www.eventbrite.com/e/rough-seas-or-smooth-sailing-navigating-collaboration-agreements-tickets-32071988180?aff=weekly

Event Details
How do you develop a smart collaboration agreement? An effectively written collaboration agreement builds and strengthens a productive scientific relationship by allowing parties to enter into a mutually beneficial relationship.

How do you make sure the agreement will fit your company objectives? An effective agreement should be clear, to both the research workers and managers of both parties, laying the groundwork for moving the results of research toward commercialization. It addresses the nature of the collaboration, the responsibilities and obligations of each party, the desired outcomes and next steps beyond the currently contemplated research.

At this event, we will walk through building components of a collaboration agreement, point out and discuss key terms and provisions that help make a quality agreement. The talk with provide real world examples and focus on the following topics:
Intro to Collaboration Agreements / General provisions
Statement of objectives/work
Budget
IP
Restrictions and opportunities created by agreements
Real world examples from panel members
The panel members will share real life experiences through the R&D collaboration process and beyond. The workshop will examine key types of provisions and their effects on future development and funding opportunities. This "how to" workshop is geared towards life sciences startup
Guests will be provided supporting materials including:
Key provisions guide
Sample Collaboration agreements
This event is being hosted in conjunction with Deloitte. Deloitte is deeply committed to the life sciences industry. As an advisor to many leading health care and life sciences organizations, Deloitte has been instrumental in developing and implementing many strategies that helped shape the evolution and long-term success of this industry. At Deloitte, we serve from early-stage companies to the world's largest players. We know where you go and we can help you to realize your dreams. As with all our events, the "How to…Workshop" is informal and interactive so bring your questions with you!

Speakers' Biographies:

Angela Rusakova | Lead Client Service and Audit Partner, Deloitte & Touche LLP
Angela has 20 years of experience serving both public and private companies with a focus on the life sciences industry. She works with companies in all stages of growth, from start-ups to SEC registrants. Her technical background includes complex accounting issues such as revenue recognition, equity, derivatives, stock-based compensation, and acquisitions. Angela has been involved in financing and M&A transactions, including initial public offerings, offerings in leveraged buyouts, and several secondary shares offerings. She has extensive international experience and is a certified public accountant in the United States and the United Kingdom. Angela also served as a CFO before returning to public accounting in 2003.

Yelda Kaya | Sr. Director Transactions, Johnson & Johnson Innovation
Yelda is the Senior Director of Transactions in Johnson & Johnson Innovation Center, California.
Leveraging a diverse career practicing emergency medicine, corporate law and business development, Yelda brings extensive experience to transactions delivering a unique breadth of deals across sectors with an established track record of successfully leading, structuring, negotiating and executing complex deals over the last 10 years.
Yelda joined the Johnson & Johnson family from GSK's worldwide business development group. She holds a MBBS, LLB and MBA from the University of Melbourne.

William J. Newell | CEO, Sutro Biopharma
Mr. Newell has over 24 years of senior management experience in the biotechnology industry. He joined Sutro Biopharma as CEO in January 2009. Previously, he served as the President of Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell also was Chief Business Officer and Senior Vice President at publicly-traded QLT, Inc. and served in several senior management positions at public-traded Axys Pharmaceuticals, Inc. For the 16 years prior to joining Axys, Mr. Newell practiced corporate law in the San Francisco Bay Area. He is presently a member of the Board at Symic Bio. Mr. Newell is also a Board member on BIO's Emerging Companies Section and a member of the Board and of the Executive Committee of the California Life Sciences Association.

Lesley Stolz | Head of JLABS, CA, Johnson & Johnson Innovation, JLABS
Dr. Stolz has 20 years of business and corporate development experience working for companies that have been both technology platform and therapeutics focused. After two years negotiating partnering deals for Johnson & Johnson Innovation at the California Innovation Center, Lesley joined the JLABS team as Head of JLABS, CA, to participate in the mission of helping to catalyze new companies in the healthcare ecosystem. Prior to joining Johnson & Johnson Innovation, she held executive positions with BioTime, Inc., Sutro Biopharma, Inc., and Sunesis Pharmaceuticals where she was responsible for corporate strategy, fundraising and all aspects of partnering. Earlier in her career, she served as Senior Director, Business Development for Aerovance, Inc. and for GPC Biotech AG in Munich, Germany from 2002 to 2006. She also served in senior management positions at Cell Genesys, Discovery Partners International and Axys Pharmaceuticals. During her career she has work on over 45 collaboration agreements helping shape effective opportunities for early stage companies. Dr. Stolz received her Ph.D. in chemistry, and conducted postdoctoral research at Harvard Medical School's Department of Biochemistry and Molecular Pharmacology.
****

BioScience Forum, Wednesday Evening, May 24, 2017

Topic: "Circulatory Factors as Modulators of Brain Function and Aging"
Speaker: Tony Wyss-Coray, Ph.D., Professor of Neurology, Stanford University, Co-Founder, Chairman of Scientific Advisory Board, Alkahest
Date and Time: Wednesday, May 24, 2017, 6:00 PM - 9:00 PM
6 pm - 7 pm networking
7 pm - 8 pm dinner
8 pm - 9 pm presentation
Location: The Holiday Inn, 275 S Airport Blvd, South San Francisco, California 94080, USA
Event Registration ($3 service fee will apply)
Pre-Registration
$50.00
On-Site Registration
$60.00
Pre-Registration ends Monday, May 22nd, at 9 pm
Cash or check accepted on the day of the event
$10 discount for full-time students
Register at (www.biosf.org)
Or you can pay with a check made out to "BioScience Forum" and sent to:
BioScience Forum
1442A Walnut Street, #308

Berkeley, CA 94709-1405
Please do not mail checks later than Thursday, May 18th
If paying with check, do not complete online registration with Cvent

Topic Description
Brain aging leads to cognitive decline and is the main risk factor for sporadic forms of neurodegenerative diseases including Alzheimer's disease. While brain cell and tissue intrinsic factors are likely key determinants of the aging process recent studies from our lab and others document a remarkable susceptibility of the brain to circulatory factors. Thus, blood borne factors from young mice or humans are sufficient to slow aspects of brain aging and improve cognitive function in old mice, and vice versa, factors from old mice are detrimental for young mice and impair cognition. We discovered tissue inhibitor of metalloproteases (TIMP)-2 to be sufficient and, in part, necessary to mediate the cognitive benefits of young human plasma on aged mouse brains. We are trying to understand the molecular basis of these observations and rejuvenation in general and explore their relevance for neurodegeneration and dementia.

Speaker Biography
Tony Wyss-Coray is a professor of Neurology and Neurological Sciences at Stanford University, the Co-Director of the Stanford Alzheimer's Disease Research Center, and a Senior Research Career Scientist at the Palo Alto VA. His lab studies brain aging and neurodegeneration with a focus on age-related cognitive decline and Alzheimer's disease. The Wyss-Coray research team is following up on earlier discoveries, which showed circulatory blood factors can modulate brain structure and function and factors from young organisms can rejuvenate old brains. These findings were voted 2nd place Breakthrough of the Year in 2014 by Science Magazine and presented in talks at Global TED, the World Economic Forum, and Google Zeitgeist.

Wyss-Coray is the co-founder of Alkahest, a company developing plasma-based therapies to counter age-related diseases such as Alzheimer's. Current studies in his lab focus on the molecular basis of the systemic communication with the brain by employing a combination of genetic, cell biology, and –omics approaches in killifish, mice, and humans and through the development of bio-orthogonal tools for the in vivo labeling of proteins.

Wyss-Coray is the inventor on multiple patents and the recipient of an NIH Director's Pioneer Award, a Zenith Award from the Alzheimer's Association, and a NOMIS Foundation Award.

****

Bio2Device Group, Tuesday Morning, May 30, 2017

Topic: "Emerging regulations and their impact on the medical device industry"
Speaker: Patrick Lee, Senior Director of RA/QA, Vascular Dynamics
Date and Time: Tuesday, May 30, 2017, 8:30 am
Location: Sunnyvale City Council Chambers- 456 West Olive Ave., Sunnyvale
Event Details
There is no cost or reservation required for morning meetings.

Topic Description

The presentation will focus on a number of upcoming changes in regulations and how they might impact medical device companies, especially those based in the US. These changes include Brexit, the new MDR (EU Medical Device Regulations), and changing FDA administration, and its related activities. MDR are the new regulations that replaces the EU MDD and is to be fully implemented by 2020. The FDA changes will have administrative and legislative components. How will they affect U.S. companies? In Europe, Brexit will add to the burden of international regulatory and marketing requirements of medical products in the UK. We will consider how Brexit, as an example, will impact the launching and marketing of new medical devices in the UK. An introduction of the new MDR will be made. Some characteristic details have major implication for any medical device company – factors such as fighter reporting requirements, greater design control measures, more clinical data, more clinical reporting using Eudamed. An economic analysis will show how MDR will affect new products going to be EU.
In the U.S., FDA changes will impact U.S. companies because most will need to continue to use the U.S. regulatory ground work as a basis for overseas submission. A lower regulatory hurdle in the U.S. may not necessarily be an advantage when a company will still need to undertake he continuum of regulatory requirements to bring a product to market. What is the implication of regulation for any company? What is the probability of a company actually loosing economic interests under the new administration?

Speaker Bio
Patrick Lee is the Senior Director of QA/RA for Vascular Dynamics. Previlously, Patrick the Director of Regulatory Affairs at Iridex Corp in Mountain VIew, CA. Patrick is involved in regulatory activities worldwide in obtaining regulatory approvals and compliance. Prior to Iridex, Patrick served in various management positions in regulatory affairs at Bay area medical device companies. The product categories that he has worked in include neuro-implants, cardiovascular devices, cellular therapy device, laser and other electro-mechanical devices, blood processing, stem cell harvesting, drug-delivery devices, and others. Patrick has over 25 years of experience in FDA-regulated industries including health-care, medical device, and nutritional products. Patrick received his Chemical Engineering BS from Cornell, MS in engineering from Columbia, and MBA from the Anderson School at UCLA. He is a licensed Professional Engineer in the states of New Jersey and California and holds several patents. Patrick holds the US Regulatory Affairs RAC (US) designation and CQA.

****
Event: Drug-Induced Liver injury (DILI): risk assessment in drug discovery and clinical development
Speakers: William Treem (J&J), Michael Rothenberg (Genentech), Weida Tong (NCTR/FDA), Yazen Alnouti (UNMC), Donna Dambach (Genentech), Cyrus Khojasteh (Genentech), Kenneth Brouwer (Qualyst), Gary Peltz (Stanford Medical)
Date and Time: Friday, June 2, 2017, 9:00 -16:00
Location: Crowne Plaza, Foster City, CA
Registration fee (USD): Regular: $195; Academic: $125; Students & Unemployed: $35;
Registration: http://www.PBSS.org
Further Information:
Registration deadline: 5/31/2017 (it will close sooner if the seating cap is reached)

Topic Description

Drug-induced liver injury (DILI) continues to be a leading cause of attrition during small molecule drug development, withdrawal post-marketing, and cautionary / restrictive labeling. Hepatotoxicity risk is difficult to predict based on the various etiologies that encompass DILI, with unknown factors driving patient susceptibility towards hepatic stress and injury, coupled with the poor concordance of preclinical species to identify human hepatotoxicants in vivo. However, retrospective analysis over the past 50 years has identified several factors associated with DILI that include but are not limited to physicochemical properties of the drug, dose, metabolism and disposition, and signals in a battery of in vitro assays. As such, the pharmaceutical industry and regulatory agencies alike are focused on more comprehensive risk assessment to reduce and/or mitigate DILI risk in drug discovery and early development. This full-day mini-symposium is centered on contemporary perspectives on DILI from an academic, industry, and regulatory perspective, with focused talks addressing mechanisms of DILI, clinical presentation and management, hepatotoxicity risk assessment in drug discovery, and novel tools (including biomarkers) emerging in the field.

Minisymposium topics and speakers:
TBD - William Treem, MD, J&J
The challenges of potential DILI in early clinical development - Michael Rothenberg, MD, PhD, Genentech
Liver Toxicity Knowledge Base – A knowledge base approach for drug-induced liver injury - Weida Tong, PhD, NCTR/FDA
The role of bile acids in DILI and liver diseases - Yazen Alnouti, PhD, University of Nebraska Medical Center (UNMC)
Multi-parametric assessment of hepatotoxicity risk in drug discovery - Donna Dambach, VMD, PhD, Genentech
Reactive metabolites: from assessment to removal in drug discovery - Cyrus Khojasteh, PhD, Genentech
Risk Assessment for Cholestatic Hepatotoxicity: Integrating Transporter Inhibition and FXR Mediated Regulation into a Predictive In Vitro Assay - Kenneth R. Brouwer, PhD, RPh, Qualyst Transporter Solutions
Human Liver Engineering: From Safer Drugs to Liver Regeneration - Gary Peltz, MD, PhD, Stanford University Medical School

WIB Plenary Session, Monday Late Afternoon, June 19, 2017
Event: Plenary Event at BIO Convention: "Pitch Perfect Challenge"
Date and Time: Monday, June 19, 2017, 4:30 p.m. – 7:30 p.m. PST
Location: Manchester Grand Hyatt, 1 Market Place,San Diego, CA 92101
Fees: Member - $60 and Non Member - $90
Details and registration at http://womeninbio.org/eventdetails.aspx?EventId=31272
On-Line Registration Deadline

Event Description
Inviting. Supporting. Succeeding.

Adjacent the Biotechnology Innovation Organization (BIO) International Convention, please join us for our signature annual WIB Plenary Event on Monday, June 19, 2017, at the beautiful Manchester Grand Hyatt from 4:30 p.m. - 7:30 p.m.
The evening will open with keynote speaker Carol Gallagher, Pharm.D, Partner of New Enterprise Associates, with a presentation discussing the investment landscape and an overview of fund-raising challenges and trends.

We then move into our Pitch Challenge where women leaders in the life sciences will deliver pitches and receive valuable feedback from top female investors on presentation and delivery. If you're up for the Challenge, please apply here by Friday, April 28, 2017. Please complete the application and attach your slide deck in an email to Pitch@womeninbio.org. Participation Eligibility Criteria and Official Rules are listed in the application. Please note that we only review non-confidential materials.
The Pitch Challenge will be moderated by Simone Fishburn, BioCentury Innovations, and our prestigious panel of judges include:

- Nina Kjellson, Caanan Ventures
- Margarita Chavez, AbbVie Ventures
- Kristina Burow, ARCH Partners
- Heather Behanna, Sofinnova
- Marianne De Backer, Johnson & Johnson
- Carol Gallagher, NEA

As with all Women In Bio events, our Plenary Event encompasses an inviting and fun environment for networking as it brings together people from all corners of the life sciences industry, and spawns new career and business opportunities.
This event is not to be missed so register today!

****

JLABS, Tuesday Morning, June 20, 2017

Event: "Meet with… Novartis Venture Fund"
Date and Time: Tuesday, June 20, 2017 from 10:30 AM to 1:00 PM (PDT)
Agenda:
9:00 AM | Registration, Breakfast, and Networking
9:30 AM | Components of a collaboration agreement
10:00 AM | Panel Discussion: Implications of Components
11:00 AM | Q&A
11:30 AM | Program Close

*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due May 19, 2017. Apply Here.
Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California
Ticket Information
Fees:
Presentation
$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on June 20 (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Apply to meet one-on-one with representatives from Novartis Venture Fund. Your application will be reviewed and you will be notified of acceptance on Monday June 6, 2017. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

Event Details
Let's get more solutions to patients. The Johnson & Johnson Innovation, JLABS (JLABS) Meet with… Series helps life sciences entrepreneurs, as well as the academic community, connect with potential partners including corporate venture, VC's, Angels and other investment entities.

On June 20th Principal Christine Brennan and Life Sciences Investment and Operations Professional Giovanni Ferrara of the Novartis Venture Fund (NVF)team will be in attendance to give an overview presentation about the fund's key areas of interest and to meet 1-on-1 with companies that have been accepted after applying online.

Program Overview:
The Novartis Venture Fund founded in 1996, currently manages over $750 Million in committed capital, and has investments in ~40 portfolio companies globallyb>. NVF's strategy is to build a diverse portfolio of life science companies, across:
Biotechnology/biopharma
Medical device/diagnostics
Digital/eHealth
NVF is stage agnostic and engages in seed investments as well as later-stage investments, typically investing up to $15 - $20 million over the life of the company. In investing, NVF looks for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency.

Following the presentation, don't miss this opportunity to introduce yourself to the team during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with Novartis Venture Fund will provide an intimate forum to discuss your company

Speaker Bios:
Christine Brennan | Principal, Novartis Venture Fund
Dr. Brennan joined the Novartis Venture Fund in November 2013. Prior to joining Novartis Venture Fund, Dr. Brennan spent 3 years at Vitae Pharmaceuticals as Chief Business Officer responsible for strategy & business development. Prior to Vitae, she spent 5 years at Novartis Institutes for BioMedical Research in Strategic Alliances, most recently as Executive Director and Head of Strategy & Operations. Prior to Novartis, she held positions in business development and marketing at the biopharmaceutical companies, EnVivo Pharmaceuticals (now FORUM Pharmaceuticals), Biovail (now Valeant Pharmaceuticals) and Cogent Neuroscience. In addition, she was Director atFidelity Biosciences Group (now F-Prime Capital Partners), a venture capital company. She received her Ph.D. in neuroscience from Dartmouth Medical School in 1995 and completed a postdoctoral fellowship at the National Institutes of Health in 1999.

Giovanni Ferrara | Life Sciences Investment and Operations Professional, Novartis Venture Fund

BIO Talent Connect, 6.22.2017
BIO Talent Connect presented by BioSpace

San Diego Convention Center
Ballroom 20AB
Register at
http://www.biospace.com/jobs/seekersignin.aspx/?ReferPage=/jobs/careerfairregister.aspx?careerfairid=293
Thursday, June 22, 2017
2:00pm to 6:30pm



About BIO Talent Connect

BIO Talent Connect is not another career fair. It's a unique opportunity to network with peers, industry leaders and hiring managers at the hottest biopharma companies in an open, inviting and efficient format.

BIO International Convention is the largest global gathering of life sciences innovators and the optimal place to bring leading employers together with talented professionals.

Who should attend?

All Life Sciences professionals are invited to attend, including PhD and Postdoc candidates as well as professionals with Life Sciences experience in any discipline. Your resume is required to register.

What companies will be there?

Company leaders, scientists and hiring managers are looking forward to meeting you at BIO Talent Connect to discuss a wide variety of global career opportunities. A full list of companies will be posted to this page prior to the event.

Should I still register if I can't attend?

Yes! If you are unable to attend the event, but interested in life science career opportunities, you should still register as soon as possible. Employers will be able to view your resume and contact you.

****